Freedom Biosciences Emerges From Stealth With $10.5 Million Seed Financing To Develop Next-Generation Ketamine And Psychedelic-Based Mental Health Treatments
Freedom Biosciences Emerges From Stealth With $10.5 Million Seed Financing To Develop Next-Generation Ketamine And Psychedelic-Based Mental Health Treatments
08/23/22, 11:31 AM
Location
san franciscoMoney raised
$10.5 million
Industry
biotechnology
Round Type
seed
Freedom Biosciences, a clinical-stage biotechnology platform developing next-generation viable and efficacious ketamine and psychedelic therapeutics, today emerged from stealth with $10.5 million in seed financing. MBX Capital led the round and was joined by PsyMed Ventures, Village Global and The Yale Startup, among others. The new financing will help the company advance its current lead ketamine program as well as further multiple additional exploratory programs.
Company Info
Location
san francisco, california, united states
Additional Info
Freedom Biosciences is a clinical-stage biotechnology platform developing next-generation viable and efficacious ketamine and psychedelic therapeutics. The company was co-founded by Dr. John Krystal, Chair of the Department of Psychiatry at Yale University, and Dina Burkitbayeva, founder of PsyMed Ventures, alongside Hunter Bouchard and Morgan Springer. Freedom Biosciences launched from stealth in 2022 and is backed by MBX Capital, Village Global and PsyMed Ventures, among others. To learn more, visit: www.freedombio.co